And its investments in AI could, eventually, lead to important monetization opportunities even beyond advertising, perhaps ...

Wondering if Recursion Pharmaceuticals at around US$4.67 a share is priced for its potential or still misunderstood by the market? This article walks through what the current numbers may be telling ...

Eli Lilly is a safer way to capitalize on AI-driven drug discovery.

Why Recursion Pharmaceuticals Is On Investors’ Radar Recursion Pharmaceuticals (RXRX) has been drawing attention after recent trading, with the stock closing at $4.67. Investors are weighing this ...

Recursion claims that its artificial-intelligence-backed drug discovery platform gets smarter each time it pinpoints a new drug candidate—which is why, even with several of those candidates already in ...

Small-cap biotech companies can deliver outsized returns over the long run if they develop breakthrough medicines that go on to generate massive sales. However, some of these smaller drugmakers aren't ...

Recursion Pharmaceuticals (NASDAQ:RXRX) has experienced notable share price fluctuations in 2025, falling 27% year-to-date and trading over 55% beneath its 52-week high of $12. In spite of this ...

Management expressed confidence in achieving further milestones in 2025, supported by partnerships with Roche and Sanofi. CEO Gibson noted that the partnership milestones generated $45 million in cash ...

Recursion Pharmaceuticals is a TechBio company trying to apply artificial intelligence (AI) to the new drug-discovery process. The first placebo-controlled trial results from Recursion Pharmaceuticals ...

On sci-fi TV shows like Star Trek, when a doctor needs to cure a disease, they often ask the computer to simulate complex visualizations or go through databases for potential cures. In real life, ...